The TNF receptor-associated periodic syndrome (TRAPS): emerging concepts of an autoinflammatory disorder.
about
Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease (*)Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapiesLighting the fires within: the cell biology of autoinflammatory diseasesInvolvement of the same TNFR1 residue in mendelian and multifactorial inflammatory disorders.Co-inherited mutations of Fas and caspase-10 in development of the autoimmune lymphoproliferative syndromeRole of tumour necrosis factor (TNF)-α and TNFRSF1A R92Q mutation in the pathogenesis of TNF receptor-associated periodic syndrome and multiple sclerosis.Potential of IL-1, IL-18 and Inflammasome Inhibition for the Treatment of Inflammatory Skin Diseases.Defective regulation of CXCR2 facilitates neutrophil release from bone marrow causing spontaneous inflammation in severely NF-kappa B-deficient mice.Concerted action of wild-type and mutant TNF receptors enhances inflammation in TNF receptor 1-associated periodic fever syndrome.Pathogenesis of familial periodic fever syndromes or hereditary autoinflammatory syndromes.The phenotype of TNF receptor-associated autoinflammatory syndrome (TRAPS) at presentation: a series of 158 cases from the Eurofever/EUROTRAPS international registry.Falling into TRAPS--receptor misfolding in the TNF receptor 1-associated periodic fever syndromeMitochondrial reactive oxygen species promote production of proinflammatory cytokines and are elevated in TNFR1-associated periodic syndrome (TRAPS)Variable intrafamilial expressivity of the rare tumor necrosis factor-receptor associated periodic syndrome-associated mutation I170N that affects the TNFR1A cleavage site.First report of circulating microRNAs in tumour necrosis factor receptor-associated periodic syndrome (TRAPS).Effects of the histone deacetylase inhibitor ITF2357 in autoinflammatory syndromes.Interleukin-1 as a common denominator from autoinflammatory to autoimmune disorders: premises, perils, and perspectivesTumour necrosis factor receptor trafficking dysfunction opens the TRAPS door to pro-inflammatory cytokine secretion.The novel S59P mutation in the TNFRSF1A gene identified in an adult onset TNF receptor associated periodic syndrome (TRAPS) constitutively activates NF-κB pathwayUpdated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004.Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005"Periodic fever" without fever: two cases of non-febrile TRAPS with mutations in the TNFRSF1A gene presenting with episodes of inflammation or monosymptomatic amyloidosis.Clinical significance of P46L and R92Q substitutions in the tumour necrosis factor superfamily 1A geneUpdated consensus statement on biological agents for the treatment of rheumatic diseases, 2006.A novel tumour necrosis factor receptor mutation in a Finnish family with periodic fever syndrome.Abnormal disulfide-linked oligomerization results in ER retention and altered signaling by TNFR1 mutants in TNFR1-associated periodic fever syndrome (TRAPS)The TNFRSF1A R92Q mutation is frequent in rheumatoid arthritis but shows no evidence for association or linkage with the diseaseMolecular mechanisms in genetically defined autoinflammatory diseases: disorders of amplified danger signaling.Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007The genetics of the amyloidoses: interactions with immunity and inflammation.Autoinflammatory diseases.Periodic fever syndromes: a diagnostic challenge for the allergist.Biological treatments: new weapons in the management of monogenic autoinflammatory disordersMonogenic autoinflammatory diseases: concept and clinical manifestations.The Central Role of Anti-IL-1 Blockade in the Treatment of Monogenic and Multi-Factorial Autoinflammatory Diseases.Monogenic autoinflammatory syndromes: state of the art on genetic, clinical, and therapeutic issuesRecurrent fever and rash.Efficacy of etanercept in the tumor necrosis factor receptor-associated periodic syndrome: a prospective, open-label, dose-escalation study.Monogenic autoinflammatory diseases: disorders of amplified danger sensing and cytokine dysregulation.The inherited autoinflammatory syndrome: a decade of discovery.
P2860
Q24631660-3EF6B327-3C8D-45E3-9D02-C84C530E4143Q26799747-77CF87EE-75B4-4A76-B939-702820477690Q26827163-DDA051C4-A646-4236-96E7-19FC66EA3166Q30352433-22C3EC8F-C99D-4AB3-94C2-924ED9FD120DQ30838565-2561090B-A7DA-4FD1-8DD0-2A07C3CB9252Q33352461-0406488E-4670-40A6-A820-7462E8177E56Q33710807-04AE9C4B-6771-4EEF-8A11-23269601F034Q33936499-49D846C5-EA72-476B-BF0A-79E16A34EBD8Q34006517-44969563-17FB-4453-89AB-54F6FEF39443Q34560380-A168AF1C-6711-42EF-9D58-5F4F718E0FDEQ34607571-58FD99EF-B12F-4570-BDC7-4D8EF0AAF16EQ34657952-561387AF-1F4B-4875-8BD6-E2BBE25061C8Q34681297-71478392-E5DB-452B-BD71-53F8C0EFA9E3Q34781635-0F2393B8-303A-47D5-B1D6-CB7A60B384F2Q34997023-833C7E2F-2F92-415B-BDA8-2F11271F52A4Q35016951-75D74D40-4468-47E8-AD46-35EB2DB43499Q35133812-C40F29C7-3ACC-4372-8E50-38CBDC632209Q35485350-2BF5D921-4E9C-4C89-89C4-2E0B6A8DF28FQ35559391-F1CFF6DE-50A8-457B-8C4E-B7A1574E625BQ35579352-6CC2A6C6-E479-4E89-B09D-09769A9D8717Q35579517-9BB02F8D-3050-45FC-BD95-05BFAF35E81AQ35637417-A29168C3-7D24-4328-AE4F-CF279DEDD895Q35637824-51157781-1EEF-489E-9892-10498C19878FQ35638252-56B77B2F-F1CC-48B7-BF8A-02B61681E712Q35823352-175DE673-B116-49E1-8CAB-D3599DC5FF0DQ35849941-614FD2B7-BE9B-438D-9D02-1C5965CC068CQ35953451-9FE310A2-B7B0-4319-BDD0-6719F4C59E60Q36041225-94AE84AB-F98F-47F8-AF0E-4E04695C715EQ36171750-7F8FC076-CE27-4A0F-88AF-C2FC24409A6BQ36534748-17B38FF2-C6ED-41E5-B457-D59210C93CCFQ36714318-E6D128ED-20DA-4DFF-AAB3-39A373896283Q36993432-54F8858D-B81A-46BE-B605-095530320987Q37077564-3C853CD1-D0D1-4044-8DE2-FA29404510E2Q37162157-27D917CD-E2B6-464E-AB84-229A5AC24A05Q37270409-52A79490-6571-4B6A-B10B-77FFA27B9F63Q37299354-1936164B-331D-4B62-872E-C0118A4E4F54Q37407556-E6F8043A-8945-4DEC-A6C6-494961049E00Q37438706-FB62A838-EF2A-46ED-A9B7-9A0E446682FEQ37466515-7FBD3CE6-3CE9-4515-833C-321DF6369EA0Q37600652-AE6DFD25-6379-4D14-B4E3-121F568F03DD
P2860
The TNF receptor-associated periodic syndrome (TRAPS): emerging concepts of an autoinflammatory disorder.
description
2002 nî lūn-bûn
@nan
2002 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
The TNF receptor-associated pe ...... an autoinflammatory disorder.
@ast
The TNF receptor-associated pe ...... an autoinflammatory disorder.
@en
The TNF receptor-associated periodic syndrome
@nl
type
label
The TNF receptor-associated pe ...... an autoinflammatory disorder.
@ast
The TNF receptor-associated pe ...... an autoinflammatory disorder.
@en
The TNF receptor-associated periodic syndrome
@nl
prefLabel
The TNF receptor-associated pe ...... an autoinflammatory disorder.
@ast
The TNF receptor-associated pe ...... an autoinflammatory disorder.
@en
The TNF receptor-associated periodic syndrome
@nl
P2093
P1433
P1476
The TNF receptor-associated pe ...... an autoinflammatory disorder.
@en
P2093
Daniel L Kastner
Elizabeth Drewe
Elizabeth M McDermott
Harjot K Singh
Ivona Aksentijevich
Keith M Hull
Kondi Wong
Richard J Powell
P304
P356
10.1097/00005792-200209000-00002
P407
P577
2002-09-01T00:00:00Z